Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin’s B Cell Lymphoma
Condition(s):Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed B-cell Non-Hodgkin LymphomaLast Updated:April 14, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed B-cell Non-Hodgkin LymphomaLast Updated:April 14, 2023Completed
Condition(s):Lymphoma, B-Cell; CAR-TLast Updated:January 18, 2024Recruiting
Condition(s):Mature B-Cell LymphomaLast Updated:February 24, 2023Recruiting
Condition(s):B Cell LymphomaLast Updated:January 9, 2020Terminated
Condition(s):B-cell LymphomaLast Updated:February 25, 2019Unknown status
Condition(s):B-cell Lymphoma Recurrent; B-cell Lymphoma RefractoryLast Updated:February 7, 2024Active, not recruiting
Condition(s):B-cell LymphomaLast Updated:December 7, 2021Completed
Condition(s):B-cell LymphomasLast Updated:November 4, 2014Completed
Condition(s):B-cell Non-Hodgkin’s LymphomaLast Updated:July 5, 2022Recruiting
Condition(s):B-cell LymphomasLast Updated:May 9, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.